

Mekinist

Oman · access guide

How to access Mekinist from Oman, the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Omani patient diagnosed with BRAF V600 mutant advanced melanoma, or another approved BRAF-mutant indication, may receive a prescription for Mekinist (trametinib) from their treating medical oncologist, typically in combination with Tafinlar (dabrafenib). Mekinist is FDA-approved in the United States. In the Kingdom of Oman, Mekinist may not always be locally registered or routinely stocked, which is why your oncologist may be coordinating a named-patient import pathway on your behalf.

This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Mekinist is an oral selective MEK1/MEK2 kinase inhibitor. It is used in combination with dabrafenib (Tafinlar) in BRAF V600 mutant cancers, improving both efficacy and tolerability versus BRAF-inhibitor monotherapy. The manufacturer is Novartis. Dosing is typically 2 mg orally once daily, taken on an empty stomach. Monitoring includes cardiac function (LVEF), ocular events (retinopathy, retinal vein occlusion), interstitial lung disease, skin rash, and hypertension. Your oncologist will confirm BRAF status and combination planning.

Is Mekinist legally importable into Oman?

Yes, through Oman Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC) named-patient import framework, administered via the administering hospital's importing pharmacy and the DGPADC Pharmaceutical Product Regulation department.

The framework rests on four anchors: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. Applications are typically filed by the tertiary centre's importing pharmacy on the physician's behalf.

How the pathway works, step by step

1. **Consultation with your treating oncologist.** The decision to prescribe Mekinist in combination with Tafinlar is clinical, based on BRAF status and disease burden. Your oncologist documents the rationale.
2. **Administering facility identification.** A Omani tertiary oncology centre with an importing pharmacy files on behalf of the physician.
3. **DGPADC named-patient application.** Your physician or the hospital's importing pharmacy files an application with DGPADC including clinical rationale, combination regimen, patient identifier, product details, and chain-of-custody plan.
4. **US-side sourcing.** Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
5. **Temperature-controlled shipment.** Mekinist tablets require controlled storage; shipments travel with temperature logging and tamper-evident packaging end to end.
6. **Arrival and dispensing support.** Your oncologist remains the treating clinician. Reserve Meds coordinates re-supply ahead of cycle end to avoid treatment gaps.

What documentation your physician needs

Your physician will typically need to provide:

- A clinical rationale letter confirming BRAF status, tumour type, combination regimen, prior therapies, and Mekinist as the indicated treatment
- Verification of their Oman medical licence (DGPADC)
- A current prescription naming the product, strength, and quantity
- Patient identifier (anonymised reference preferred)
- The planned treatment cadence (continuous daily therapy with monthly re-supply)

Reserve Meds provides a physician documentation kit bundling the templates DGPADC reviewers expect to see for oncology oral therapies under named-patient import.

Costs and timing

Mekinist's US cash-pay drug-only reference price for a 30-day supply sits in an indicative 2026 drug-only range (delivered quote issued at intake) of roughly USD 13,000-15,000. The combination partner (Tafinlar) is costed separately. Logistics, DGPADC documentation handling, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.

Indicative timing for first shipment arrival after cohort intake opens is 7-14 days from the moment a complete DGPADC application is submitted. Subsequent re-supply cycles are generally faster once the pathway is established.

Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Mekinist specifically, we provide:

- **Sourcing.** Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- **Documentation.** Regulatory documentation package for your physician and for DGPADC review, covering the full combination regimen.
- **Logistics.** Temperature-controlled shipment and chain-of-custody coordination.
- **Concierge case lead.** A named point of contact for your family and your physician throughout the process.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

Frequently asked

Is this legal in Oman? Yes, when executed through the DGPADC named-patient framework with appropriate documentation. See our trust and compliance page.

Can Mekinist and Tafinlar be coordinated together? Yes, the combination is standard of care; we coordinate both components under a single case.

What about cardiac and ocular monitoring? MEK inhibitors require periodic LVEF and ophthalmology review. Your oncologist will arrange this. We coordinate supply, not clinical surveillance.

Will private insurance cover this? Cash-pay is the default. Some Omani private insurers reimburse named-patient imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

Reserve Meds

reserved for you.

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.
reservemeds.com · hello@reservemeds.com